7.18
-0.10
(-1.37%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 7.17 - 7.38 |
| 52 week | 2.56 - 7.53 |
| Open | 7.34 |
| Vol / Avg. | 300,904.00/361,491.00 |
| Mkt cap | 615.10M |
| P/E | - |
| Div/yield | - |
| EPS | -0.70 |
| Shares | 85.67M |
| Beta | 1.20 |
| Inst. own | 88% |
Events
Jul 31, 2013
Q2 2013 Cadence Pharmaceuticals, Inc. Earnings Release
Jun 12, 2013
Cadence Pharmaceuticals, Inc. Annual Shareholder Meeting
- 11:00AM EDT -
May 30, 2013
Cadence Pharmaceuticals, Inc. at Deutsche Bank dbAccess Health Care Conference
- 11:20AM EDT -
May 21, 2013
Cadence Pharmaceuticals, Inc. at UBS Global Healthcare Conference
- 2:00PM EDT -
May 15, 2013
Cadence Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 2, 2013
Q1 2013 Cadence Pharmaceuticals, Inc. Earnings Conference Call
May 2, 2013
Q1 2013 Cadence Pharmaceuticals, Inc. Earnings Release
Mar 7, 2013
Q4 2012 Cadence Pharmaceuticals, Inc. Earnings Conference Call
Mar 5, 2013
Cadence Pharmaceuticals, Inc. at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -5.77% | -161.35% |
| Operating margin | -33.62% | -152.79% |
| EBITD margin | - | -129.87% |
| Return on average assets | -5.66% | -61.97% |
| Return on average equity | -11.39% | -96.90% |
| Employees | 206 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 12481 High Bluff Drive
SAN DIEGO, CA 92130
United States - Map
+1-858-4361400 (Phone)
+1-858-4361401 (Fax)
SAN DIEGO, CA 92130
United States - Map
+1-858-4361400 (Phone)
+1-858-4361401 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Cadence Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics utilized primarily in the hospital setting. Cadence Pharmaceuticals' initial focus is on hospital-use anti-infectives. Acetavance is an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever.
Officers and directors
| Cam L. Garner | Independent Chairman of the Board | |
| Theodore R. Schroeder | President, Chief Executive Officer, Director | |
| William R. LaRue | Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary | |
| Hazel M. Aker J.D. | Senior Vice President, General Counsel, Secretary | |
| Scott A. Byrd | Senior Vice President, Chief Commercial Officer | |
| Malcolm Lloyd-Smith | Senior Vice President - Regulatory Affairs, Quality and Clinical | |
| Brian G. Atwood | Independent Director | |
| Samuel L. Barker Ph.D. | Independent Director | |
| Michael A. Berman M.D. | Independent Director | |
| James C. Blair Ph.D. | Independent Director |